ALLR · Allarity Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Jensen Thomas CEO | ▲ Buy | Grant | 596,734 Shares held | 1/28/2026 | View profile |
| Graff Jeremy R. Director | ▲ Buy | Grant | 381,644 Shares held | 1/7/2026 | View profile |
| Ervin Jeffrey S CFO | ▲ Buy | Grant | 150,000 Shares held | 1/28/2026 | View profile |
| Epshinsky Alexander CFO | ▲ Buy | Grant | 85,051 Shares held | 1/22/2025 | View profile |
| McLaughlin Gerald W. Director | ▲ Buy | Grant | 70,000 Shares held | 1/28/2026 | View profile |
| Hoeiland Jesper Director | ▲ Buy | Grant | 25,000 Shares held | 1/7/2026 | View profile |
Transaction History
| Jensen Thomas | ▲ Buy | Grant | 200,000 | $0 | 1/28/2026 |
| McLaughlin Gerald W. | ▲ Buy | Grant | 45,000 | $0 | 1/28/2026 |
| Ervin Jeffrey S | ▲ Buy | Grant | 150,000 | $0 | 1/28/2026 |
| Graff Jeremy R. | ▲ Buy | Grant | 133,333 | $0 | 1/7/2026 |
| Hoeiland Jesper | ▲ Buy | Grant | 25,000 | $0 | 1/7/2026 |
| Graff Jeremy R. | ▲ Buy | Option Exercise | 39,494 | — | 9/30/2025 |
| Graff Jeremy R. | ▼ Sell | Tax Withholding | 14,613 | $23K | 9/30/2025 |
| Epshinsky Alexander | ▲ Buy | Grant | 29,496 | $0 | 1/22/2025 |
| Jensen Thomas | ▲ Buy | Grant | 396,734 | $0 | 1/22/2025 |
| Graff Jeremy R. | ▲ Buy | Grant | 144,441 | $0 | 1/22/2025 |
| Graff Jeremy R. | ▲ Buy | Grant | 118,483 | $250K | 9/30/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Allarity Therapeutics expands lab capabilities and highlights DRP technology
Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.
Allarity Therapeutics expands lab capabilities and highlights DRP technology. Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.